GLP-1 ব্যাখ্যা: ভারতীয় রোগীদের সম্পূর্ণ গাইড
Semaglutide বা tirzepatide শুনে right for you কি না ভেবেছেন—আপনি একা নন। GLP-1 RA worldwide type 2 diabetes ও obesity approach বদলেছে—India exception নয়। guide GLP-1 কী, body-তে কীভাবে কাজ, Indian patient RSSDI, ICMR, CDSCO framework-এ access, cost, safety navigate-এ কী matter। newly diagnosed type 2, normal-range BMI central obesity, family member option explore—drug class literacy brand marketing নয় productive medical conversation foundation। South Asian unique metabolic pattern, lower insurance coverage, 2026 growing generic access drug-class literacy valuable।
Short answer
GLP-1 রিসেপ্টর অ্যাগোনিস্ট (GLP-1 RA) injectable ও oral ওষুধ শ্রেণি যা gut hormone mimic করে appetite কমায়, পেট খালি ধীর করে, blood sugar control উন্নত করে। ভারতে টাইপ ২ ডায়াবেটিস ও নির্বাচিত স্থূলতায় BMI ≥27.5 kg/m² বা comorbidity-সহ ≥25-এ prescribe। doctor prescription, CDSCO-approved sourcing, gradual dose titration দরকার। RSSDI ও ICMR guideline Indian clinician use shape। Kesho শুধু education—prescribe/sell নয়। purchase-এর আগে product approval verify।
Key takeaways
- •GLP-1 RA drug class—single product নয়—natural gut hormone mimic করে blood sugar improve ও appetite reduce।
- •ভারতে RSSDI ও ICMR earlier BMI threshold (≥27.5 বা comorbidity-সহ ≥25)—South Asian lower body weight-এ metabolic disease।
- •সব GLP-1 RA Schedule H prescription medicine; CDSCO unapproved import ও social-media seller-এর বিরুদ্ধে সতর্ক।
- •Benefit weeks-এ dose titration-এ build; first month nausea common, ছোট meal ও gradual dose increase-এ improve।
- •Medication Indian dietary pattern, physical activity, regular monitoring-এ best—standalone shortcut নয়।
GLP-1 কী?
GLP-1 (glucagon-like peptide-1) খাওয়ার পর gut release hormone। blood sugar rise-এ pancreas insulin signal, glucagon (blood sugar raise hormone) reduce, brain full signal। GLP-1 RA এই hormone mimic medication। drug class—single brand নয়—semaglutide, liraglutide, dulaglutide, dual GIP/GLP-1 agent tirzepatide। ভারতে Schedule H drug: registered medical practitioner valid prescription ছাড়া dispense নয়। CDSCO class প্রতিটি product approval, labelling, pharmacovigilance regulate। drug class বোঝা brand marketing trap ছাড়া informed doctor conversation। অনেক patient প্রথম GLP-1 RA metformin ও lifestyle alone HbA1c control insufficient, বা modest BMI scale-এ excess weight insulin resistance fatty liver drive। RSSDI clinical practice recommendation glycaemic target first-line miss-এ type 2 diabetes pathway-এ GLP-1 RA important option recognise।
GLP-1 রিসেপ্টর অ্যাগোনিস্ট
Pancreas, brain, gut-এ GLP-1 receptor activate করে blood sugar control improve ও appetite reduce medication।
GLP-1 রিসেপ্টর অ্যাগোনিস্ট body-তে কীভাবে কাজ করে?
GLP-1 RA নিলে sequence-এ কয়েকটি ঘটে। প্রথম pancreas insulin release stimulate—blood glucose elevated হলে only, sulfonylurea-এর মতো older diabetes drug-এর চেয়ে low blood sugar risk কম। দ্বিতীয় gastric emptying slow—food stomach-এ longer, smaller portion satisfied। তৃতীয় brain appetite centre-এ act, craving emotional eating trigger reduce। STEP programme semaglutide, SURMOUNT tirzepatide trial lifestyle change-এ meaningful weight loss HbA1c improvement। dose titrate upward weeks-এ gradually build—first two-three months patience। first weeks nausea common, body adapt slow dose increase (dose titration) doctor guide—improve। Indian patient large traditional meal-এ delayed stomach emptying unfamiliar; smaller frequent portion single heavy dinner-এর চেয়ে better।
ভারতে GLP-1-এর approved use কী?
ভারতে GLP-1 RA primarily adult type 2 diabetes diet, exercise, metformin first-line insufficient। RSSDI class position better glycaemic control, cardiovascular risk, obesity, CKD, other medicine hypoglycaemia concern। obesity management ICMR national guideline RSSDI consensus Western-এর চেয়ে lower BMI threshold—South Asian lower body weight metabolic complication। BMI 27.5 kg/m²+, বা prediabetes, fatty liver, hypertension, dyslipidaemia comorbidity-সহ 25 kg/m²+ appropriate patient pharmacotherapy consider। final eligibility treating physician full medical history, current medicine, investigation review। cardiovascular outcome trial established heart disease high-risk patient glucose beyond benefit। type 1 diabetes indicated নয়; diabetic ketoacidosis insulin substitute নয়।
Kesho GLP-1 medication prescribe বা sell করে না। article educational। personalised medical advice qualified endocrinologist, internal medicine specialist, cardiologist consult।
Indian BMI threshold Western guideline-এর চেয়ে কেন আলাদা?
Indian South Asian population frequently "thin-fat" phenotype: scale-এ normal/modest BMI, higher visceral (belly) fat, lower muscle mass। insulin resistance, fatty liver, early type 2 diabetes link। BMI 26 Mumbai Europe same BMI-এর চেয়ে metabolic risk বেশi। RSSDI ICMR earlier intervention recommend। conventional chart "normal" weight central obesity, elevated HbA1c, ultrasound fatty liver doctor GLP-1 broader metabolic plan discuss। waist circumference South Asia men often 90 cm+, women 80 cm+ clinician BMI alongside practical measure। body composition scale number alone—Western online calculator Indian patient misleading self-assessment।
ভারতে GLP-1 medication legally access কীভাবে?
ভারতে GLP-1 RA innovator product ও increasingly CDSCO-approved generic semaglutide patent development follow। monthly out-of-pocket approximately ₹8,000–₹25,000 molecule, dose, city—most family significant expense। licensed pharmacy valid prescription purchase। CDSCO advisory unapproved import, compounded formulation, social-media steep discount without prescription warn। medication CDSCO approval, proper labelling, batch, expiry verify। cold-chain injectable pen প্রথম ব্যবহারের আগে 2°C–8°C refrigeration। first use-এর পর most pen 30°C room temperature several weeks manufacturer CDSCO-approved guideline। metro pharmacist cold-chain familiar; tier-2 tier-3 dispensing counter storage confirm।
GLP-1 RA common diabetes medicine-এর সঙ্গে compare
- Feature: Primary action — GLP-1 RA: GLP-1 hormone mimic; appetite reduce — Metformin: liver glucose output reduce — Sulfonylureas: insulin release stimulate
- Feature: Weight effect — GLP-1 RA: Usually loss — Metformin: Neutral/slight loss — Sulfonylureas: Often gain
- Feature: Hypoglycaemia risk alone — GLP-1 RA: Low — Metformin: Very low — Sulfonylureas: Moderate to high
- Feature: Route in India — GLP-1 RA: Injection (weekly/daily) or oral — Metformin: Oral — Sulfonylureas: Oral
- Feature: Typical RSSDI position — GLP-1 RA: After metformin if targets unmet — Metformin: First-line most T2D — Sulfonylureas: Declining hypoglycaemia/weight
Medically reviewed
Dr. Ananya Mehta, MD, DM Endocrinology
Consultant Endocrinologist, India
This article has been reviewed by our medical advisory team, including endocrinologists, internal medicine specialists, and cardiologists, and is based on current scientific evidence and Indian clinical guidelines. Last reviewed: June 2026.
Last medically reviewed: Jun 26, 2026